> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Ipsen’s Palovarotene NDA
- URL: https://www.fdaweb.com/panel-to-discuss-ipsens-palovarotene-nda/
- Published: 2023-05-24T12:00:00.000Z
- Updated: 2026-09-14T18:34:08.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5154521

*Federal Register* notice: FDA is announcing a 6/28 Endocrinologic and Metabolic Drugs Advisory Committee meeting. Panel members are scheduled to discuss an Ipsen Biopharmaceuticals NDA for palovarotene capsules, indicated for preventing heterotopic ossification in adults and children (females aged eight years and above and males 10 years and above) with fibrodysplasia ossificans progressiva. To view the notice, click [here](https://public-inspection.federalregister.gov/2023-11164.pdf?ref=fdaweb.com).